FDMT

4D Molecular Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1650648Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$85.0M

Net Income FY2025

$(140.0M)

EPS (Basic, as reported)

$-2.42

Net Margin FY2025

-164.4%

ROE FY2025

-27.7%

Total Equity

$506.0M

Shares Out

50M

Business description

4D Molecular Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 7 → 85 +51.6% CAGR

Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue71318321085

General & administrative(14)(17)(28)(33)(36)(47)(49)

Total operating expenses(58)(70)(89)(113)(134)(188)(245)

Operating income(51)(57)(71)(110)(113)(188)(160)

Interest & investment income2003122719

Other income (expense), net1003122719

Income tax expense—000000

Net income(49)(57)(71)(107)(101)(161)(140)

EPS — basic——($2.57)($3.32)($2.58)($2.98)($2.42)

EPS — diluted——($2.57)($3.32)($2.58)($2.98)($2.42)

Shares outstanding — basic (M)——2832395458

Shares outstanding — diluted (M)——2832395458

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.